These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27143026)

  • 1. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy.
    Sohn M; Talbert J; Moga DC; Blumenschein K
    Atten Defic Hyperact Disord; 2016 Sep; 8(3):149-58. PubMed ID: 27143026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
    Lachaine J; Sikirica V; Mathurin K
    BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
    Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
    Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
    Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
    Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
    Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada.
    Lachaine J; Ben Amor L; Pringsheim T; Burns J; van Stralen J
    J Child Adolesc Psychopharmacol; 2019 Dec; 29(10):730-739. PubMed ID: 31433205
    [No Abstract]   [Full Text] [Related]  

  • 8. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.
    Zimovetz EA; Beard SM; Hodgkins P; Bischof M; Mauskopf JA; Setyawan J
    CNS Drugs; 2016 Oct; 30(10):985-96. PubMed ID: 27530525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
    Prasad S; Arellano J; Steer C; Libretto SE
    Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson TM; Xie J; Erder MH; Dammerman RS; Robertson B; Wu EQ
    Am J Manag Care; 2014 Sep; 20(9):711-21. PubMed ID: 25365746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
    Hong J; Dilla T; Arellano J
    BMC Psychiatry; 2009 Apr; 9():15. PubMed ID: 19366449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
    Chan E; Fogler JM; Hammerness PG
    JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebec.
    Lachaine J; De G; Sikirica V; Van Stralen J; Hodgkins P; Yang H; Heroux J; Ben Amor L
    Can J Psychiatry; 2014 Nov; 59(11):597-608. PubMed ID: 25565476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
    Jain R; Katic A
    Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
    Huang YS; Tsai MH
    CNS Drugs; 2011 Jul; 25(7):539-54. PubMed ID: 21699268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.
    Wu EQ; Hodgkins P; Ben-Hamadi R; Setyawan J; Xie J; Sikirica V; Du EX; Yan SY; Erder MH
    CNS Drugs; 2012 Jul; 26(7):581-600. PubMed ID: 22712698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
    Molife C; Haynes VS; Nyhuis A; Faries DE; Gelwicks S; Kelsey DK; Alatorre CI
    Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.
    Zimovetz EA; Joseph A; Ayyagari R; Mauskopf JA
    Eur J Health Econ; 2018 Jan; 19(1):21-35. PubMed ID: 28093662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.
    Huss M; Chen W; Ludolph AG
    Clin Drug Investig; 2016 Jan; 36(1):1-25. PubMed ID: 26585576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of the Preschool ADHD Treatment Study (PATS) Children Growing Up.
    Vitiello B; Lazzaretto D; Yershova K; Abikoff H; Paykina N; McCracken JT; McGough JJ; Kollins SH; Greenhill LL; Wigal S; Wigal T; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 2015 Jul; 54(7):550-6. PubMed ID: 26088659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.